Research

Hormonal

Therapeutic reduction of central adiposity via bariatric surgery or incretin-based drugs significantly reduces the risk of heart failure hospitalizations and worsening heart failure events in patients with HFpEF, whereas blood pressure lowering alone yields only modest benefits unrelated to the magnitude of BP reduction.

For HFpEF patients, focusing solely on blood pressure medication is insufficient. Prioritizing significant weight loss through bariatric surgery or incretin-based medications (like semaglutide or tirzepatide) is critical, as these interventions directly reduce the hormonal and mechanical drivers of heart failure, leading to a 50-60% reduction in worsening heart failure events.

GoodSupportsHIGH confidence
Therapeutic amelioration of excess adiposity by bariatric surgery or incretin-based drugs appears to have substantial effects on the evolution and progression of HFpEF, with reported reductions of 40% to 60% in the risk of heart failure hospitalizations.
Milton Packer et al. · Journal of the American College of Cardiology · 2025

Why this rating

Based on large observational studies, Mendelian randomization, and multiple RCTs (though BP trials were not HFpEF-specific, weight loss trials were).

Source

Central Adiposity or Hypertension

Milton Packer et al. · Journal of the American College of Cardiology · 2025

DOI 10.1016/j.jacc.2025.08.036

narrative_reviewCited 13×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →